Prevnar 13

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaMultiple MyelomaPneumoniaImmunodeficiencySickle Cell DiseaseHIV-1 Infection

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Prevnar 13

Merck & Co.

Approved

12

Blenoxane

SSequus Pharmaceuticals

Preclinical

253

Zofran

Novartis

Preclinical

24

Tafasitamab

Incyte

Preclinical

75

Nuvigil

NNuvo Research GmbH

Preclinical

16

Systemic Therapy

Bristol-Myers Squibb

Preclinical

17

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—8

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

39

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

210

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

1Show 17 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity24 trials

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Completed·Merck & Co.·Phase 3·NCT02225587·400 enrolled

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Completed·GSK·Phase 3·NCT01000974·4,003 enrolled

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Completed·Merck & Co.·Phase 3·NCT03480763·652 enrolled

Show 21 more trials

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT01702428·5,016 enrolled

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Completed·Merck & Co.·Phase 1/2·NCT02531373·338 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Completed·Merck & Co.·Phase 3·NCT03893448·1,720 enrolled

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Completed·GSK·Phase 2·NCT01616459·953 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Completed·GSK·Phase 3·NCT01681992·4,538 enrolled

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01553279·284 enrolled

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

Unknown status·NNuron Biotech Inc.·Phase 2·NCT01732198·220 enrolled

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Terminated·Pfizer·Phase 2·NCT03550313·565 enrolled

Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Completed·Merck & Co.·Phase 2·NCT02547649·690 enrolled

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Completed·Pfizer·Phase 2·NCT03313037·444 enrolled

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Completed·Merck & Co.·Phase 2·NCT01513551·692 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT02184572·1,742 enrolled

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

Completed·Merck & Co.·Phase 3·NCT03885934·606 enrolled

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Completed·Merck & Co.·Phase 2·NCT02987972·1,051 enrolled

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

Recruiting·CanSino Biologics Inc.·Phase 3·NCT07017777·600 enrolled

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Completed·Merck & Co.·Phase 2·NCT02573181·253 enrolled

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

Completed·Sanofi·Phase 1·NCT06698198·175 enrolled

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Completed·Merck & Co.·Phase 3·NCT01337167·1,473 enrolled

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT01978093·600 enrolled

Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

Completed·Merck & Co.·Phase 1/2·NCT02037984·341 enrolled

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

Completed·Merck & Co.·Phase 3·NCT03950622·1,205 enrolled

Adult3 trials

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Completed·Merck & Co.·Phase 3·NCT03950856·2,340 enrolled

A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays

Completed·GSK·Phase 4·NCT02072525·359 enrolled

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

Completed·Johnson & Johnson·Phase 1/2·NCT03819049·836 enrolled

Immunodeficiency2 trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Completed·Merck & Co.·Phase 3·NCT03480802·302 enrolled

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

Completed·Merck & Co.·Phase 3·NCT03921424·407 enrolled

Clinical Trial2 trials

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Completed·SSinovac Research and Development Co., Ltd.·Phase 1·NCT06183216·140 enrolled

A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Completed·JJiangsu Province Centers for Disease Control and Prevention·Phase 3·NCT02494999·1,200 enrolled

Infants2 trials

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Completed·Merck & Co.·Phase 3·NCT03692871·2,409 enrolled

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Completed·Merck & Co.·Phase 3·NCT03620162·900 enrolled

15 more indications

Pneumococcal Vaccines1 trial

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Completed·Pfizer·Phase 1·NCT03642847·104 enrolled

Immune Response1 trial

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Completed·GSK·Phase 2·NCT05412030·388 enrolled

Sickle Cell Disease1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Completed·Merck & Co.·Phase 3·NCT03731182·104 enrolled

Pneumonia1 trial

Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status

Completed·SSt. Antonius Hospital·Phase 4·NCT02141009·60 enrolled

Pneumococcal Immunization1 trial

The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13

Completed·LLakehead University·Phase 4·NCT02370069·138 enrolled

Lenalidomide1 trial

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01349569·19 enrolled

Vaccine1 trial

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

Completed·Merck & Co.·Phase 2·NCT01215188·1,152 enrolled

Allogeneic Hematopoietic Stem Cell Transplant Recipient1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Completed·Merck & Co.·Phase 3·NCT03565900·277 enrolled

Infections1 trial

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Completed·GSK·Phase 2·NCT01545375·1,806 enrolled

Multiple Myeloma1 trial

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02851056·14 enrolled

Pneumococcal Disease1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Completed·Merck & Co.·Phase 3·NCT03547167·1,515 enrolled

Stem Cell Transplant1 trial

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Terminated·LLudwig Institute for Cancer Research·Phase 1·NCT02716805·6 enrolled

Lymphoma1 trial

Vaccine Responses in Patients With B Cell Malignancies

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Approved·NCT05170399·350 enrolled

HIV-1 infection1 trial

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Active, not recruiting·VVA Eastern Colorado Health Care System·Phase 1·NCT03729778·100 enrolled

Unspecified1 trial

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Completed·Merck & Co.·Phase 3·NCT01340937·2,808 enrolled

Details

Drug Info

Related News